Neurocognitive effects and biomarkers of psilocybin microdosing

Abstract

3.1. A topic of significant and rapidly growing interest in the public is the phenomenon of “microdosing”. Microdosing refers to consumption of a ‘subthreshold’ dose of a psychedelic substance, most commonly LSD or psilocybin. These doses involve only minimal noticeable changes in conscious experience. Early research indicates that microdosing is low risk and may have benefits for mental health and cognitive performance. To date, there have been only a small number of studies investigating the neurobiological effects of microdosing and the fundamental mechanisms involved. The proposed study will use a self-blinding design to investigate neurological, biological, and behavioral differences between microdosing and placebo conditions. These data will allow for substantial progress in our understanding of what microdosing does in the brain, and potentially elucidate neurobiological correlates of psychological effects.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

Keywords